Trial indicates that BIBF1120 may preserve lung function in patients with idiopathic Pulmonary Fibrosis (IPF).

New data presented at the 16th International Colloquium on Lung and Airway Fibrosis (ICLAF) show that Boehringer Ingelheim's investigational compound BIBF1120, a triple kinase inhibitor, may provide significant clinical benefit in patients with idiopathic pulmonary fibrosis (IPF). IPF is a progressive and severely debilitating lung disease, for which there are no approved treatments in the US or Europe and there is an unmet clinical need for effective licensed agents. Results from the Phase II TOMORROW study, presented by Professor Luca Richeldi from the Centre for Rare Lung Diseases at the University of Modena and Reggio Emilia, Policlinico Hospital, Modena, Italy, show that 12 months' …